BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

Semaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands

AT A GLANCE 12 generic makers with a public launch in India, selling 20 brands between them Rs 1,290 lowest stated monthly price, for vials...

October 08, 2026 | Analysis

Quanterix and Innovita Secure China Regulatory Approvals for SIMOA-Based Alzheimer's Disease Biomarker Tests

Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a lead...

October 09, 2026 | News

Bausch + Lomb Advances Oral Dry AMD Therapy BL1243 Following FDA Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced progress i...

October 08, 2026 | News

Energenesis, Yoo Young Pharm Explore Korean Development of Diabetic Foot Ulcer Therapy

Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YY...

October 07, 2026 | News

EpiSign, Geneyx Partner to Integrate Genomic and Epigenomic Analysis for Rare Diseases

Collaboration brings EpiSign's comprehensive DNA methylation episignature analysis together with the Geneyx genomic and multi-omics analysis platform EpiS...

October 07, 2026 | News

Thermo Fisher Proteomics Study Uncovers Over 2,500 New Genetic-Protein Associations

Thermo Fisher’s complementary proteomic technologies uncovered more than 2,500 new biological associations: Initial findings from the PRECISE-SG100...

October 06, 2026 | News

Celaid Therapeutics Raises $2.6M to Advance CLD-001 Towards US Clinical Trials

Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 Celaid Therapeutics Inc...

October 06, 2026 | News

FDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirto...

October 06, 2026 | News

Genmab’s Rina-S Shows Durable Response in Platinum-Resistant Ovarian Cancer

Treatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median durat...

October 06, 2026 | News

Bambusa Doses First Patient in Subcutaneous Cohort of Phase I BBT001 Trial

First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration ...

October 05, 2026 | News

Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma

Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...

October 02, 2026 | News

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of Bispecific ADC TJ102

Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), announced that the first patient h...

October 02, 2026 | News

Telix Secures FDA Fast Track Designation for BiPASS Prostate Cancer Imaging Programme

FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate ca...

October 01, 2026 | News

Lilly’s Retatrutide Delivers 20.8% Weight Loss in Phase III Obesity and Type 2 Diabetes Trial

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half...

October 01, 2026 | News

Stay Connected